Recombinant Human Serum Albumin/Interferon alpha2a Fusion Protein Phase I Study in Chinese Healthy Volunteers

NCT01901198 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Healthy Volunteers

Interventions

BIOLOGICAL: Human Serum Albumin/interferon alpha2a 300-1200 mcg single dose S.C.
BIOLOGICAL: Peginterferon 180 mcg single dose S.C.

Sponsor

Beijing Bio-Fortune Ltd.